Clinical Development and Presentations - The company will present three posters for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2025 International Conference [1] - The posters include details on the EFZO-FIT trial design, real-world treatment patterns, and the incidence, prevalence, and mortality of pulmonary sarcoidosis in the US [2] - The EFZO-FIT trial is the largest placebo-controlled trial in pulmonary sarcoidosis, with topline data expected in Q3 2025 [1][2] About Efzofitimod - Efzofitimod is a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD) [3] - It selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent fibrosis progression [3] - The company is investigating efzofitimod in the global Phase 3 EFZO-FIT study for pulmonary sarcoidosis and the Phase 2 EFZO-CONNECT study for systemic sclerosis-related ILD [3] About aTyr - aTyr is a clinical-stage biotechnology company focused on translating tRNA synthetase biology into new therapies for fibrosis and inflammation [4] - The company's discovery platform leverages a proprietary library of domains derived from all 20 tRNA synthetases to uncover novel signaling pathways [4] - Efzofitimod is the lead therapeutic candidate, targeting immune-mediated disorders that cause inflammation and progressive fibrosis in the lungs [4]
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference